HomeInfrastructurePune Mixture Spider Claim Awaits FDA Verification

Pune Mixture Spider Claim Awaits FDA Verification

A Pune resident has claimed that he found an insect resembling a spider inside a packet of Haldiram’s ‘Mixture Farsan’ and has urged the Food and Drug Administration (FDA) to investigate the complaint. The allegation has not been independently verified, and no test result or official action has been reported in the supplied account.

Kaivalya Pethkar, a resident of Warje, said he purchased the snack packet and was about to open it when his son brought it to him. Pethkar said he checked the contents before consumption and allegedly noticed what appeared to be a spider inside the sealed product.

“Fortunately, I checked it before eating and noticed what appeared to be a spider inside. This is a serious matter, and if food products are reaching consumers in this condition, it raises concerns about food safety,” Pethkar was quoted as saying.

Pethkar has asked the FDA to collect and test a sample of the product, examine its batch details and review the manufacturing process. He has also sought appropriate legal action against the company if an investigation establishes violations of food safety regulations.

The complaint places the next step with the food safety authority, which would need to examine the product and relevant records before determining whether any violation occurred. The supplied report does not state whether the FDA has collected a sample, opened an investigation or issued a response.

The incident also highlights the importance of traceability in packaged food complaints. Batch information, product samples and laboratory testing can help authorities determine whether a reported contamination incident is linked to manufacturing, packaging, storage or another point in the supply chain. However, no such findings have been provided in the account available for this report.

Until an official examination or laboratory result is made public, the claim remains an allegation by the consumer and should not be treated as an established finding against the product or its manufacturer. The matter remains pending any response or action from the FDA.



RELATED ARTICLES

Most Popular

Latest News